Last reviewed · How we verify
Hidradenitis suppurativa — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Abrilada | Adalimumab-Afzb | AbbVie | TNF blocker | Tumor necrosis factor-alpha (TNF-alpha) | 2002-01-01 | |
| Humira | ADALIMUMAB | AbbVie | TNF blocker | Tumor Necrosis Factor-alpha (TNF-alpha) | 2002-01-01 | |
| CYLTEZO | ADALIMUMAB-ADBM | BOEHRINGER INGELHEIM | Tumor necrosis factor | |||
| Humira | Humira | Sohag University | Tumor necrosis factor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AbbVie · 2 drugs in Hidradenitis suppurativa
- BOEHRINGER INGELHEIM · 1 drug in Hidradenitis suppurativa
- Sohag University · 1 drug in Hidradenitis suppurativa
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hidradenitis suppurativa:
- Hidradenitis suppurativa treatment updates — RSS
- Hidradenitis suppurativa treatment updates — Atom
- Hidradenitis suppurativa treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hidradenitis suppurativa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hidradenitis-suppurativa. Accessed 2026-06-10.
Related
- Hidradenitis suppurativa full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing